ANS Biotech

Dr. Caussade holds a Doctorate in Pharmacy (1983) and a Ph.D. in Biochemistry (1985). Prior to founding ANS Biotech, he gained more than 20 years of biology research and leadership experience (Director of Biology) in drug discovery and preclinical development of novel drugs in the R&D divisions of pharmaceutical (UPSA, Bristol Myers Squibb) and biotech (CEREP) companies. He has developed an expertise in the field of pain and successfully led several R&D projects focused on the characterization of new active drugs for the treatment of inflammatory pain and neuropathic pain. He is the co-author of 20 scientific papers and over 30 published abstracts.

Dr. Diop earned his Ph.D. in Molecular and Cellular Biology in 1985. From 1988 until 2002, he held many senior leadership positions in pharmaceutical companies (Jouveinal, Parke-Davis, Pfizer) where he actively contributed to drug development projects in digestive motility and visceral pain. He was especially in charge of R&D programs designed to evaluate the efficacy of new compounds for the treatment of IBS and IBD. In 2002, he was appointed as Head of Probiotics and Digestive Functions in a food company (Danone). In 2004, Dr. Diop became an independent scientific R&D consultant for pharmaceutical and food industry. In 2008, he joined ANS Biotech as Chief Scientific Officer and Chief Operational Officer. He has co-authored 6 patents, 38 research articles and about 60 published abstracts.

Dr. Darbaky earned his Ph.D. in Neurosciences in 2004. During two years spent at Sanofi, he developed new innovative models of chemotherapy-induced neuropathies in rodents. Then, he moved to Neorphys, a biotech company where he was in charge of the biology and pharmacology research activities focused on the discovery of novel analgesics. In 2007, he joined ANS Biotech to manage fee for services activities and R&D projects in pain pharmacology.